S84 Systematic Literature Review of the Ability of the IBDQ-32 to Detect Meaningful Change in Ulcerative Colitis Health Indicators

tacrolimus enema, 3 were discontinued for the following reasons: 1 was not consistent with the nightly enemas, 1 was transferred for colostomy at another hospital, and 1 was discontinued due to pain. For the 2 that were able to continue with the treatment, they took the medication daily for over a year and reached Remission/Inactive Disease on PUCAI and PCDAI, respectively. These patients were found tohave improvedparaclinical indicatorswitha reduction in CRPand Calprotectin levels. These 2 patients also showed clinical improvement with a decrease in experiencing symptoms of abdominal pain, rectal bleeding, or urgency. Two patients reported adverse e ﬀ ects while on rectal tacrolimus. One experienced a burning sensation in the rectum, while another experienced pain during the administration of the enema. Conclusion(s): The results of this case report suggest that rectal tacrolimus may be an e ﬀ ective therapeutic alternative in patients with UC or CD with refractory proctitis and has a generally safe side e ﬀ ect pro ﬁ le.